Cited by 197Dermatology and Skin DiseasesAsthma and respiratory diseasesContact Dermatitis and Allergies

Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo‐controlled and double blind pilot study

Heil, Peter Maximilian, Maurer, Dieter, Klein, Brigitte, Hultsch, Thomas, Stingl, Georg·2010·JDDG: Journal der Deutschen Dermatologischen Gesellschaft

Abstract

Background Our understanding of the pathogenic role of IgE in atopic dermatitis is incomplete. We asked whether blocking free IgE would alter the course of the disease. Patients and methods We administered either omalizumab, a humanized monoclonal mouse antibody against IgE, or placebo subcutaneously for 16 weeks to 20 atopic dermatitis patients and measured immunological and clinical disease parameters. Results Omalizumab (I) reduced free serum IgE, (II) lowered surface IgE and FcɛRI expression on different peripheral blood mononuclear cells, (III) reduced the saturation of FcɛRI with IgE, (IV) increased the number of free FcɛRI and (V) lowered the number of IgE+, but not of FcɛRI+ cells in skin. The in vivo relevance of these results is evidenced by the increase in the threshold allergen concentration required to give a type I hypersensitivity reaction in the titrated skin test. While not significantly altering the clinical disease parameters, omalizumab treatment led to an improvement of the atopy patch test results in single patients, i.e. an eczematous reaction upon epicutaneous allergen challenge. Conclusions The interference with immediate and delayed type skin tests may imply that a therapeutic benefit of omalizumab treatment, if present at all, would be seen in patients with acute rather than chronic forms of the disease.

Integrity signals

Registry

Crossref · 10.1111/j.1610-0387.2010.07497.x

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Omalizumab failed to show convincing results in proof-of-concept studies and single cases.

    “strategies aimed at depleting IgE with the anti-IgE biologic omalizumab failed to show convincing results in proof-of-concept studies and single cases107,108.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Heil, P. M., Maurer, D., Klein, B., Hultsch, T., & Stingl, G.
Affiliations
  • Medical University of Vienna (AT)
  • Johannes Gutenberg University Mainz (DE)
Venue
JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Publisher
Wiley
Published
2010-11-25
Volume
8
Issue
12
Pages
990-998
ISSN
  • 1610-0379 (ISSN-L)
  • 1610-0387
OpenAlex
W1512818159
Cited by
197
References
38
Citations by year
2026: 1 · 2025: 11 · 2024: 3 · 2023: 10 · 2022: 6 · 2021: 14 · 2020: 10 · 2019: 14 · 2018: 12 · 2017: 19 · 2016: 24 · 2015: 24 · 2014: 13 · 2013: 15 · 2012: 16
FWCI
13.89
Type
journal article
Language
en
Open access
closed
Locations
  • JDDG Journal der Deutschen Dermatologischen Gesellschaft (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
  • Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
Keywords
omalizumab, atopic dermatitis, IgE, FcεRI, immediate hypersensitivity, atopy patch test, chronic atopic dermatitis
MeSH terms
Omalizumab, Adolescent, Adult, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Dermatitis, Atopic, Double-Blind Method, Female, Humans, Immunoglobulin E, Injections, Subcutaneous, Male, Middle Aged, Pilot Projects, Skin Tests, Placebo Effect, Treatment Outcome, Anti-Allergic Agents, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review